Search - tctmd.com

Displaying 1 - 20 of 102

Sort: Relevancy | Date

News Daily News

February 2026 Dispatch for the CV Team

L.A. McKeown

February 18, 2026

News Daily News

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

L.A. McKeown

February 06, 2026

News Daily News

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

Caitlin E. Cox

February 02, 2026

News Opinion CV Team Dispatch

January 2026 Dispatch for the CV Team

L.A. McKeown

January 16, 2026

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Conference News AHA 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Michael O'Riordan

November 08, 2025

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Caitlin E. Cox

October 22, 2025

News Daily News

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Michael O'Riordan

August 01, 2025

News Daily News

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

L.A. McKeown

July 24, 2025

News Daily News

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Michael O'Riordan

June 25, 2025

News Daily News

Amylin Analogue Boosts Weight Loss When Added to GLP-1

L.A. McKeown

June 24, 2025

News Daily News

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

Michael O'Riordan

April 25, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

News Daily News

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

Caitlin E. Cox

February 26, 2025

News Daily News

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

Michael O'Riordan

February 20, 2025

News Daily News

US Football Fans Are Flooded With Ads for Unhealthy Foods

Michael O'Riordan

January 30, 2025

News Opinion CV Team Dispatch

January 2025 Dispatch for the CV Team

L.A. McKeown

January 24, 2025

News Daily News

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

Michael O'Riordan

December 04, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

News Daily News

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

L.A. McKeown

October 23, 2024

Advertisement

February 2026 Dispatch for the CV Team

Oral GLP-1s Provide Benefit in HF Patients: SOUL Subanalysis

Nearly 150 Million US Adults Eligible for CKM Syndrome Meds

January 2026 Dispatch for the CV Team

Year in Review: Top Prevention Stories of 2025

Evolocumab Cuts MACE Risk in Patients Without Prior MI, Stroke: VESALIUS-CV

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

Glipizide, Commonly Used Sulfonylurea, Linked to Greater CV Risks

Key Subgroups of HF Patients Missing Out on SGLT2 Inhibitors: Registry Data

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Amylin Analogue Boosts Weight Loss When Added to GLP-1

Medicaid Patients With Type 2 Diabetes Face Hurdles Getting Cardioprotective Meds

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

GLP-1 Drugs in Diabetes Don’t Raise Suicidality Risk, New Data Confirm

‘Arbitrary’ Hodgepodge of Composite Endpoints Used Across ASCVD Trials

US Football Fans Are Flooded With Ads for Unhealthy Foods

January 2025 Dispatch for the CV Team

Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 Top-line Results

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

SOUL: Oral Semaglutide Cuts CV Events in Diabetic Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content